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In Brazil, many cases of breast and cervical cancers are only diagnosed in advanced stages. Information 
on prevention of cancer in women is increasingly available. However, prevention or early treatment 
alternatives are often not practiced. This study investigated the issues hindering the practice of prevention 
against cancer in women. A qualitative method was employed in this exploratory and descriptive study. 
The sample included thirty-three randomly selected women undergoing treatment. The survey data 
was collected at the South Parana Institute of Oncology, Ponta Grossa - PR in September 2007 using a 
semi-structured individual interview after approval by the Research Ethics Committee of the Brazilian 
College of Systemic Studies - CBES, Curitiba - PR, under protocol 0462/07, in compliance with CNS 
Resolution number 196/96. Absence of symptoms, embarrassment, long waiting list for treatment, and 
indifference to the campaigns of prevention were some obstacles encountered. A lack of information 
about cancer and its causes and consequences was the biggest issue found regarding the acceptance of 
prevention of cancer in women. The pharmacist, in the role of educator in the prevention of cancer in 
women, can emphasize the importance of regular prevention practices and highlight the implications of 
late treatment, disseminating information that can have greater impact on society.
Uniterms: Pharmaceutical care. Cancer/prevention. Breast cancer. Cancer/uterine cervix.
No Brasil, muitos casos de câncer de mama e de colo uterino são diagnosticados em estádios avançados. 
Informações sobre prevenção de câncer na mulher são cada vez mais frequentes. No entanto, prevenção 
do câncer na mulher e diagnóstico precoce da doença muitas vezes não se realizam. Investigaram-se as 
causas que dificultam a prevenção de câncer na mulher por método qualitativo sob modalidade exploratória 
e descritiva. A amostra incluiu trinta e três mulheres em tratamento, selecionadas ao acaso atendidas no 
Instituto Sul Paranaense de Oncologia, Ponta Grossa – PR, em setembro de 2007, por meio de entrevista 
semi-estruturada individual com aprovação do Comitê de Ética em Pesquisa do Colégio Brasileiro de 
Estudos Sistêmicos – CBES, Curitiba – PR, sob o protocolo 0462/07, cumprindo-se a Resolução CNS nº 
196/96. Ausência de sintomas, vergonha, longa espera em filas de atendimento e indiferença às campanhas 
de prevenção foram alguns obstáculos encontrados. Carência de informação sobre câncer, suas causas 
e consequências, foi a maior questão encontrada quanto à aceitação da prevenção do câncer na mulher. 
O farmacêutico como educador na prevenção de câncer na mulher pode ressaltar a importância dessa 
prática feita de modo regular e apontar implicações de tratamentos tardios, difundindo informações que 
causem maior repercussão social.
Unitermos: Atenção farmacêutica. Câncer/prevenção. Câncer de mama. Câncer de colo uterino.
INTRODUCTION
The World Health Organization (WHO, 2008) 
reports that about 30% of cancers can be prevented by 
modifying or preventing major risk factors. The practice of 
cancer prevention is to increase the number of cases diag-
nosed in the early stages of the disease and hence reduce 
mortality rates. Prevention is classified depending on the 
period of the disease that it tackles. Primary prevention is 
characterized by procedures performed before the onset of 
the disease, secondary refers to those initiated following 
onset of the disease course, but without symptoms (Thuler, 
2003). In women, cancer prevention is very important, 
particularly in Brazil where many cases of breast cancer 
and cervical cancer are diagnosed only at advanced stages 
(Ministry of Health [INCA], 2005). Breast and cervical 
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cancers, respectively, are the main causes of death from 
cancer in the female population. However, despite the 
existence of prevention programs around the world, the 
rate of adherence to such initiatives remains low in many 
regions (WHO, 2005). But what are the barriers to cancer 
prevention in women? What are the conditions that hinder 
or delay the demand for regular medical care?
Breast cancer
The greatest risk factors contributing to a women 
contracting breast cancer are related to family and per-
sonal history, late reproduction, use of certain drugs, 
race, and age (CDC, 2007). Factors such as obesity after 
menopause, breast density, sedentary lifestyle, radiation 
treatments in breast and alcohol consumption are also 
relevant and should therefore also be considered (NCI, 
2005). More than half of breast cancer cases occur in de-
veloped countries due to the aforementioned factors, and 
high incidence rates occur in part because of good results 
in the programs of secondary prevention of the disease, 
which tend to reduce mortality rates (Parkin, Fernandez, 
2006). Primary prevention of breast cancer is not fully 
possible because of genetic factors and the reproduction of 
independent controls (Ministry of Health [INCA], 2005). 
In contrast, secondary prevention provides early diagnosis 
through breast examination and mammography. The cur-
rent priority in the National Health System (SUS) is the 
performing of breast examination in clinical practice, and 
mammography performed in women who present changes 
on clinical examination. 
Cervical cancer 
Cervical cancer is identified as the second most 
common cancer among women around the world (Minis-
try of Health [INCA], 2005), corresponding to 15% of all 
cancers occurring in women (Martins, Thuler, Valente, 
2005). The main cause of cervical cancer is infection by 
the human papillomavirus (HPV) whose main route of 
transmission is sexual (NCI, 2005). It should be empha-
sized that both the rate of incidence and mortality cannot 
be reduced significantly because about half of all cases 
are diagnosed at advanced stages (Ministry of Health 
[INCA], 2003). Cervical cancer is preventable because 
the development of precursor lesions are slow (Derchain, 
Longatto, Son, Syrjanen, 2005) as shown in Figure 1. Ca-
ses diagnosed at early stages of the disease or as precursors 
may be cured in all situations (Ministry of Health [INCA], 
2004), since cervical cancer is one of the most treatable 
cancers if identified early and treated effectively (WHO, 
2007). Cervical cancer can be completely prevented and 
curable at a cost, and considered low risk when screening 
for precursor lesions is associated with the diagnosis, tre-
atment and appropriate medical care (Lewis, 2004). Scre-
ening for cervical cancer is accomplished by means of the 
Papanicolaou test and, according to Brazilian guidelines, 
the examination should be performed among women in 
the 25 to 59 year age range (Ministry of Health [INCA], 
2005). Primary prevention of cancer must be done through 
sex education and the elimination of smoking, because, 
although a secondary factor for cervical cancer, smoking 
is an important risk factor for other cancers (Ministry of 
Health [INCA], 2005). 
The role of the pharmacist in cancer prevention
It is essential that health professionals work toward 
improving patient care through provision of quality 
information, expertise and humanism in the profession. 
The pharmacist must be understood in this context as an 
educator in the prevention of cancer in women. In fact, 
there are deficiencies in the health system, in professional 
preparation, in the way information is transmitted to the 
population and mainly in the implementation of preventi-
ve methods of cancer in women. The pharmacist can and 
should cater to the needs of society, because the public 
have shown increasing concern and interest in information 
on drugs and therapies, as well as in problems related to 
their health (Zubioli, 2004). Pharmacists must dedicate the 
time to consider the desires, preferences and needs of the 
patient in terms of their health, and pharmacists should be 
committed and continue to focus once practicing (Peretta, 
Ciccia, 2000). Currently, the Brazilian Consensus on Phar-
maceutical Care recommends that this practice is based 
on health education, guidance, care and dispensing phar-
FIGURE 1 - Natural history of cervical cancer. CIN: cervical 
intraepithelial neoplasia. Adapted from: Cervix cancer 
screening. Lyon, IARC Press, 2005 (IARC Handbooks of 
Cancer Prevention, Vol 10).
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macists, as well as on pharmacist therapeutic monitoring, 
while recording the activities proposed to evaluate results 
(Vieira, 2007). Pharmaceutical care must be implemented 
on three basic fronts: pharmacy orientation service, de-
velopment of skills in the community, and encouraging 
community action (PAHO, 2002). In identifying health-
related needs, professionals can develop projects focused 
on the priorities found in a community, albeit education, 
information or participation based. However, the pharma-
cist also contributes little in terms of health education or 
prevention on diseases such as cancer. The promotion of 
activities that allow clarification and guidance on cancer 
prevention is as important as the provision of appropriate 
treatment for patients with cancer.
MATERIAL AND METHODS
We used a qualitative method and an exploratory and 
descriptive approach based on semi-structured individual 
interview. The questions prepared, both descriptive and 
inquiry, were applied in the form of pre-structured ques-
tions that focused on the issues preventing or hindering 
access to health care in the prevention of recurrent cancer 
in women, the obstacles related to early identification 
and treatment of cancer diagnosed late, and relevance of 
campaigns to prevent cancer in women in the view of the 
patients interviewed. Data collection through interviews 
was carried out exclusively by the lead researcher and took 
place in September 2007 at the South Parana Institute of 
Oncology (ISPON) in Ponta Grossa – Paraná State. The 
sample included 33 women undergoing treatment of breast 
cancer or cervical cancer under public or private health 
systems, who were at early or advanced stages. In accor-
dance with Resolution CNS 196/96, the data collection 
was initiated after project approval by Research Ethics 
Committee of the Brazilian College of Systemic Studies - 
CBES, Curitiba, protocol number 0462/07. All participants 
subsequently agreed to take part in writing by signing 
informed consent forms. The results were structured ba-
sed on the concepts proposed by Bardin (cited Triviños, 
2006) according to categories of topics covered during 
the interview in order to better understand the results and 
characterize the responses given.
RESULTS AND DISCUSSION 
The data obtained in this study showed that problems 
arise in the prevention of cancer in women vary and can 
be associated with level of education of each interviewee, 
insufficient care in the public health system, economic 
issues and lack of specialists (Table I).
Obstacles related to behavioral habits
Among the reasons that prevent or hinder access to 
health care in the prevention of recurrent cancer in women, 
included the perceived lack of need for medical attention 
in the absence of symptoms because many women were 
not familiar with the concept of prevention. E1: Oh dear, 
I did not feel anything, why go to the doctor? E29: In 
my day we just resorted to the doctor when something 
bothered. Do not experience gynecological problems 
was one reason that contributed to non-regularity of 
preventive examinations (Pinho, França-Junior, 2003) 
while screening should be performed in asymptomatic 
individuals identified as high risk for any given disease 
(WHO, 2005). The sense of embarrassment was another 
sentiment associated with resistance in the implementation 
of preventive examinations of the cervix (Duavy et al., 
2007) and the screening of breast cancer by mammogra-
phy (Marinho et al., 2002). E1: For an old person like 
me it is hard to pluck up the courage to do these tests. 
E30: I was too embarrassed to undress in front of the 
doctor. To this day I am embarrassed to go to the doctor. 
Exposing one’s body to a stranger is one of the important 
factors, according to the authors, for not carrying out pre-
ventive examinations. The lack of sexual activity or age 
contributes to the failure to perform regular preventive 
TABLE I - Barriers to cancer prevention in women 
Obstacles related to behavioral habits Barriers related to health services 
Absence of apparent symptoms 
Embarrassment regarding exams
Advanced age
Lack of time 
Lack of sexual activity 
Fear of results 
Economic factors
Indifference to prevention campaigns 
Long wait in lines for treatment
Lack of professional humanism
Delay in test results through public health 
Late referral to medical oncologists 
Lack of oncologists at the health center 
Poor performance of health workers in preventing cancer 
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examinations or to discontinuing follow-up (Cesar et al., 
2003). Based on data collected in this study, we observed 
that some women became sexually inactive at the time and 
thought it unnecessary to go for regular medical attention, 
where ignoring the association between chronic infection 
and the human papillomavirus is the main cause for the 
development of cervical cancer (WHO, 2007). E6: I was 
not more preventive because I am a widow. E7: As I’ve 
been separated a long time, I did not think I needed a 
doctor. E30: I thought to do preventive checks every 
year was something for younger women, I went only 
once in a while. The lack of time to go to the doctor was 
an equally important reason pointed out by interviewees 
and is considered a barrier to prevent cancer in women 
(Pinho, França-Junior, 2003). E2: The problem is that 
these consultations are time consuming; I cannot take 
a day off work! E8: Can I get a sick note for this sort of 
consultation? Lack of availability of time for doctors, not 
having anyone to leave their children with or being absent 
at work, were frequent explanations for the women, and 
their main concern was the fear of giving a bad impression 
at work because they had left their jobs, even temporarily. 
Advanced age was also one of the reasons given for not 
carrying out preventive examinations (Lucarini, Campos, 
2007). E8: After my last child was born, I stopped going 
to consultations. E29: I did not think that at my age the 
disease would appear. E9: I thought that old people did 
not need to keep up consultations. Generally, women 
interviewees aged over 60 did not believe it necessary 
to perform routine medical prevention because they felt 
immune from having this type of disease with advancing 
age. Among the obstacles related to the identification and 
/ or treatment of cancer diagnosed late, was that fear of 
treatment or the confirmation of the result had become 
an excuse for some women to ignore the disease. E3: I 
was afraid of what the family would say, the shock, you 
know? I did not believe that I had cancer. During cancer 
treatment, women have emotional, psychological and 
physical characteristics that affect their lives significantly 
and for doctor and family it is essential to overcome these 
effects (Maluf, Mori, Barros, 2005). E13: I was just sick 
thinking about how horrible it was! Losing my hair? It’s 
even worse when I ask about the disease. From the time 
of confirmation of the diagnosis of cancer many women 
go through internal conflicts and denial of the disease and 
search for other professionals in the hope for an alternative 
diagnosis (Maluf, Mori, Barros, 2005).
Barriers related to health services
Some patients complained that during the course of 
the Papa smear, the lack of dialogue with the health pro-
fessional creates uncertainty and doubt which are often left 
unclear. Healths professionals who focus only on the col-
lection and do not perform detailed clinical examination 
contribute many women not continuing to go for the test 
(WHO, 2007). E10: I went to consultations every year, 
but when the doctor and nurse changed I stopped going. 
The previous doctor was so good to me. The new one does 
not pay attention to me. E5: The woman who saw me 
once was so rude that I did not go anymore. The lack of 
humanism that often occurs in caring for patients before, 
during and after execution of preventive examinations can 
be an aggravating factor for both situations of early initial 
diagnosis and advanced cases of gynecologic cancer. Du-
ring mammography, a skilled professional must explain 
the importance of the procedure, how the test is performed, 
the chances of the patient feeling pain or discomfort, and 
the patient should be encouraged to answer their questions, 
allowing her to feel comfortable and confident to return 
periodically to the doctor (WHO, 2007). Humanism in 
health is the appreciation of the technical quality and ethics 
of care, coupled with recognition of the rights of the user, 
their subjective aspects and cultural references, ensuring 
that the issues of gender, ethnicity, race, economic status, 
sexual orientation and specific population groups such as 
indigenous people, workers, maroon and coastal settle-
ments are respected (Ministry of Health, 2006). Reasons 
associated with late cancer treatment included the long 
wait for appointments or test results under the public 
health system and the delay in referral performed by a 
non-oncologist. The long wait for appointments or test 
results prevents the effective participation of women in 
prevention programs, causing lost interest, leading to lack 
of participation in programs (PAHO, 2004) and thus delays 
in commencement of treatment (Lucarini, Campos, 2007). 
E15: I was feeling pain and I still had to wait two, three 
months to see the doctor! It’s absurd. E22: My problem 
was the delay in the arrival of checks made out by SUS. 
E22: I thought that preventive testing was more expen-
sive. So I waited a while to see the result. In the case of 
late referral to the oncologist, patients who were attended 
by a non-specialist reported not having been examined at 
any time during the implementation of preventive exami-
nations. Other women, in regular consultation with the 
gynecologist, said the referral to specialists occurred only 
after the symptoms worsened when the idea or suspicion 
of cancer was raised by the patients themselves or family 
and after non-pharmacological treatments failed to produ-
ce remission of symptoms. E18: My gynecologist said I 
had a cyst in my breast. The problem is that the cyst was 
growing and left liquid inside. Then he got scared and 
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sent me. E11: I saw eight different doctors and they said 
that I had nothing serious wrong with my breast. I lost a 
lot of time. E31: I went to see the doctor, but I dealt with 
the discharge for a few months as if it were an infection. 
I had never done preventive checks and he also asked me 
nothing about it. When I got worse and started to bleed, 
I decided to change doctors.
This situation occurs often for lack of information 
or knowledge by the professionals. Doctors, not oncolo-
gists, have limited knowledge about preventive measures 
recommended (Tucunduva et al., 2004), although they are 
key professionals in the prevention and early detection 
of cancer. Doctors and not oncologists consider the lack 
of other professional employees and their own lack of 
knowledge or training as key factors in the adequacy of 
the recommendations on cancer prevention (Tucunduva 
et al., 2004).
The main reasons given by women who do not 
perform preventive examinations (Papanicolaou test) are 
related to the need for health services to be more effective 
educational practices and to strategies to decrease the 
insufficient coverage of the examination, especially for 
socially vulnerable and dependent on public health care 
(Amorin et al., 2006). It is essential to educate the public 
and health professionals to recognize signs and symptoms 
of early cancer in order to contribute to cancer identifi-
cation at early stages, in a bid to increase the chances of 
success in the recommended treatment (WHO, 2005). Pre-
ventive education is necessary to ensure better coverage 
of prevention programs for cancer that can have a greater 
impact on population (Lucarini, Campos, 2007). E16: 
Yes, I think prevention campaigns are very important 
but they should appear more often on TV. E31: Isolated 
campaigns on TV do not resolve it, we need broader and 
better performance of health workers. 
Factors such as ignorance of the causes that lead to 
the development of cancer, and understanding the impor-
tance of Papanicolaou smears, the concept that cancer is 
a fatal disease, that prevention is useless and the idea that 
the cost of the Papanicolaou smear is very high, are some 
of the reasons given by women who ignore the prevention 
and early identification of cancer (Lazcano-Ponce et al. 
cited Cesar et al., 2003). Other studies on breast cancer 
and cervical cancer have associated with the factors 
described above, the direct relationship between the non-
execution of preventive examinations with low cultural 
level of women (Amorin et al., 2006; Marchi, Gurgel, 
Fonsechi-Carvasan, 2006). The lack of timely and accurate 
information about cancer in women (Cesar et al., 2003; 
Maluf, Mori, Barros, 2005; Dalcuche, 2006) sometimes 
creates misconceptions about the disease. There is a need 
to overcome beliefs such as the myth that cancer is curable 
or fatal in any situation, that there are possible treatments 
or the disease manifests in those it chooses to and that 
prevention is useless (Cesar et al., 2003). 
Pharmacists can act as health teams by tracking heal-
th problems of individuals at risk in communities through 
campaigns to warn of the disease, enabling diseases to be 
prevented by counseling individuals to make wiser choices 
about health (Soares, 2002). Pharmacists have the mission 
to serve society in accordance with the needs of the public 
at large and of individual patients, and pharmacy practice 
includes not only activities related to medicines but also 
directly related to the patient, aimed at promoting health 
and preventing disease (WHO, 2006). 
Based on these data, a roadmap was proposed con-
taining relevant information to foster cancer prevention 
in women (Table II) through various activities such as 
lectures, discussions and informative materials. The 
pharmacy and health facility can become a benchmark in 
the contribution to cancer prevention in women through 
participation of pharmacists in disseminating information 
related to cancer prevention in women.
CONCLUSION
Despite the existence of educational campaigns and 
programs for prevention of breast and cervical cancer, 
TABLE II - Proposed guidance on interventions for the prevention of cancer in women 
1) Concepts of cancer 2) Guidelines on the prevention of cancer
What is cancer 
What is breast cancer 
What is cancer of the cervix 
Importance of early diagnosis 
Symptoms (apparent or otherwise) 
Types of treatments for breast and cervical cancer
Benefits x adverse reactions associated with cancer treatments 
Specialists involved in oncology 
What is cancer prevention and who is at risk 
Prevention of breast cancer 
Prevention of cervical cancer 
Existing screening and its implementation
Regularity of preventive examinations 
Implementation of preventive examinations in public and private 
services
Causes of breast cancer and cervical cancer (risk factors)
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many women ignore cancer prevention for lack of know-
ledge about the disease, its consequences and complica-
tions, or due to personal barriers. In this study, all patients 
interviewed stated they were aware of the prevention 
campaigns against cancer in women. However, some 
interviewees reported they only realized the severity and 
importance of cancer prevention when they had to face it 
personally. Our results suggest that the quantitative survey 
data in this study be compared to findings of other studies, 
toward possible improvements in prevention campaigns, 
the health system and in women’s behavioral habits. The 
educational actions on cancer prevention in women should 
highlight the real risks and consequences of a lack of re-
gular medical follow-up, through actions designed to have 
continuous and broader social repercussions.
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